Related Experiment Video
Updated: May 1, 2026
Label-Free Quantitative Proteomics Workflow for Discovery-Driven Host-Pathogen Interactions
Published on: October 20, 2020
Novel pneumocystis antigen discovery using fungal surface proteomics
Mingquan Zheng1, Yang Cai, Taylor Eddens
1Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA.
Abstract:
Pneumonia due to the fungus Pneumocystis jirovecii is a life-threatening infection that occurs in immunocompromised patients. The inability to culture the organism as well as the lack of an annotated genome has hindered antigen discovery that could be useful in developing novel vaccine- or antibody-based therapies as well as diagnostics for this infection. Here we report a novel method of surface proteomics analysis of Pneumocystis murina that reliably detected putative surface proteins that are conserved in Pneumocystis jirovecii. This technique identified novel CD4(+) T-cell epitopes as well as a novel B-cell epitope, Meu10, which encodes a glycosylphosphatidylinositol (GPI)-anchored protein thought to be involved in ascospore assembly. The described technique should facilitate the discovery of novel target proteins for diagnostics and therapeutics for Pneumocystis infection.
Insights
Researchers developed a new surface proteomics method to identify potential targets for Pneumocystis pneumonia (PCP) therapies and diagnostics. This approach aids in discovering novel antigens for vaccine and antibody development against this serious fungal infection.
Area of Science:
- Medical Mycology
- Immunology
- Proteomics
Background:
- Pneumocystis jirovecii pneumonia (PCP) is a severe, life-threatening fungal infection primarily affecting immunocompromised individuals.
- Challenges in culturing Pneumocystis and the absence of a fully annotated genome impede the discovery of antigens for therapeutic and diagnostic development.
- Current limitations hinder the creation of effective vaccines and antibody-based treatments for PCP.
Purpose of the Study:
- To develop and validate a novel surface proteomics technique for identifying conserved antigens in Pneumocystis.
- To facilitate the discovery of novel diagnostic and therapeutic targets for Pneumocystis infections.
- To overcome limitations in organism culturing and genomic annotation for antigen discovery.
Main Methods:
- Surface proteomics analysis was performed on *Pneumocystis murina*.
- The technique reliably detected putative surface proteins conserved across *Pneumocystis* species.
- Identification of novel CD4(+) T-cell and B-cell epitopes, including the Meu10 epitope.
Main Results:
- A novel surface proteomics method was successfully established and validated.
- Putative surface proteins conserved in *Pneumocystis jirovecii* were identified.
- Novel T-cell and B-cell epitopes were discovered, including Meu10, a GPI-anchored protein involved in ascospore assembly.
Conclusions:
- The developed surface proteomics technique offers a reliable approach for identifying conserved *Pneumocystis* antigens.
- This method is expected to accelerate the discovery of novel targets for diagnostics and therapeutics against PCP.
- The findings pave the way for developing new vaccines and antibody-based interventions for *Pneumocystis* infections.
